Evaluating intermittent triple therapies for HIV
Evaluation of Intermittent Triple Therapies in Real Life
University Hospital, Strasbourg, France · NCT06578702
This study is testing how well intermittent triple therapy works and how safe it is for adults living with HIV at the University Hospital in Strasbourg.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06578702 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness and safety of intermittent triple therapy in adults living with HIV who are monitored at the University Hospital in Strasbourg. Following the validation of this treatment strategy in France through the QUATUOR trial, the study seeks to gather real-life data on its efficacy and tolerance. Participants will include those who have received intermittent treatment between January 2017 and January 2024, contributing to a better understanding of this therapeutic approach.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older living with HIV who have received intermittent triple therapy at the Trait d'Union/Infectious Diseases department in Strasbourg.
Not a fit: Patients who have not undergone intermittent triple therapy or those who oppose the reuse of their data for research purposes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into a potentially effective treatment strategy for managing HIV.
How similar studies have performed: While the intermittent triple therapy approach has shown promise in previous trials in France, this study aims to provide real-world data, making it a novel contribution to the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Adult subject (≥ 18 years old) * Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg * Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024 Exclusion criteria: * Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.
Where this trial is running
Strasbourg
- Service Le Trait d'Union - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Axel URSENBACH, MD
- Email: axel.ursenbach@chru-strasbourg.fr
- Phone: 33 3 69 55 13 52
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HIV Infections, Intermittent Triple Therapy